Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.64 |
| ▸ | BTK | Q06187 | 6/20 | 0.61 |
| ▸ | ITK | Q08881 | 6/20 | 0.61 |
| ▸ | PLCG1 | P19174 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061214 | 0.89 | BTK (0.60) | JAK3BTKITKPLCG1 | |
| SCHEMBL15740631 | 0.89 | BTK (0.60) | JAK3BTKITKPLCG1 | |
| SCHEMBL2271780 | 0.88 | JAK3 (0.65) | JAK3BTKITK | |
| SCHEMBL17413158 | 0.87 | BTK (0.61) | JAK3BTKITKPLCG1 | |
| SCHEMBL2277698 | 0.85 | JAK3 (0.61) | JAK3BTKITK | |
| SCHEMBL17412969 | 0.85 | BTK (0.59) | JAK3BTKITKPLCG1 | |
| SCHEMBL2275429 | 0.83 | JAK3 (0.59) | JAK3BTKITK | |
| SCHEMBL2274976 | 0.83 | JAK3 (0.59) | JAK3BTKITK | |
| SCHEMBL2280913 | 0.82 | JAK3 (0.59) | JAK3BTKITK | |
| SCHEMBL2277104 | 0.82 | JAK3 (0.59) | JAK3BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676778-B2 | Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2017-06-13 | — | — | US | claimed |
| EP-2922538-B1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-10-15 | — | — | US | claimed |
| EP-2922538-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | Principia Biopharma Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014081732-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2922538-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | Principia Biopharma Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2015013579-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014081732-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081732-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | JAK3 2116/4885BTK 1276/4885ITK 4014/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | JAK3 2810/4885BTK 2508/4885ITK 3393/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | JAK3 2116/4885BTK 1276/4885ITK 4014/4885 |
| US-20150291600-A1 | AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | JAK3 1/4885BTK 92/4885ITK 921/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | JAK3 2810/4885BTK 2508/4885ITK 3393/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | JAK3 3201/4885BTK 2478/4885ITK 4090/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | JAK3 3201/4885BTK 2478/4885ITK 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.